key: cord-0914019-2dbfdxq7
authors: Dal‐Ré, Rafael; Holm, Søren
title: Ethical concern regarding the UK PANORAMIC COVID‐19 trial
date: 2022-02-21
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.15275
sha: bc77bebcc6d54e497f56028c64c48af9fcee221d
doc_id: 914019
cord_uid: 2dbfdxq7

nan

started recruitment of up to 10638 adult participants that will be randomized to receive usual care plus molnupiravir vs. usual care, to assess whether this antiviral prevents hospitalization or death in higher-risk patients with confirmed positive SARS-CoV-2 PCR test result. 1 Molnupiravir conditional authorization was based on the interim results of a phase 3 trial (MOVe-OUT) that, on top of usual care, assessed molnupiravir vs. placebo. 2 MOVe-OUT included only unvaccinated non-hospitalized mild-to-moderate COVID-19 tested positive patients who have at least one risk factor for developing severe illness; these risk factors were related to renal, heart or respiratory chronic conditions, obesity, diabetes, or having >60 years of age. 3 The risks factors considered in PANORAMIC are the same (except for age: now ≥50 years) as in MOVe-OUT, but to 18-to 49-year-old participants several have been added like chronic liver disease, Down's syndrome, severe mental illness, being a care home resident or judged by the recruiting health professional to be clinically vulnerable. 1 Although participants with some risk factors in the MOVe-OUT trial were scarcely present (e.g., 29 cancer patients or 57 with chronic obstructive pulmonary disease) 3 and all participants were unvaccinated, molnupiravir's temporary authorization states that it is indicated for any tested positive for SARS-CoV-2 adult patient with at least a risk factor for developing severe illness and regardless of vaccination status. 2 PANORAMIC could be described as a trial assessing, on top of usual care, an 'intervention' (i.e., molnupiravir) vs.

'no intervention'.

The principles of the Declaration of Helsinki-to be followed by PANORAMIC investigators 1 -state that the new intervention must be tested against the best proven intervention, and that 'no intervention' could be used if participants not receiving any intervention 'will not be subject to additional risks or serious or irreversible harm as a result of not receiving the best proven intervention'. 4 PANORAMIC's sample size is based on a 33% relative reduction in hospitalization or death in the molnupiravir arm (absolute risk: 2%) relative to control arm (absolute risk: 3%). 1 So, investigators expected that 3% of participants in 'no intervention' arm (n = 160) will develop severe illness, that is, hospitalization or death.

Soon after PANORAMIC started recruitment, the NHS established requirements so any (vaccinated or unvaccinated) mild-to-moderate COVID-19 patient who is at highest risk to progress to severe illness could receive molnupiravir (or sotrovimab). 5 In PANORAMIC, there will be participants fulfilling the NHS requirements, such as patients with Down's syndrome, cirrhosis, or with chronic kidney disease: all will have 50% chance to receive 'no intervention'. We believe that PANORAMIC does not conform to the Declaration of Helsinki for unvaccinated participants fulfilling the NHS requirements since the trial is exposing these participants to Since other novel antivirals will be assessed in PANORAMIC in the future (e.g., nirmatrelvir/ritonavir), 7 investigators and the research ethics committee must ensure that eligible participants for the trial would not be worse off than they would have been outside the trial: participating in PANORAMIC must not entail the possibility of being penalized by receiving 'no intervention'. To this end, the requirements established by the NHS for the prescription of any antiviral outside PANORAMIC, must always be taken into consideration when amending the trial protocol for the evaluation of new antivirals.

This work required no funding.

There are no competing interest to declare.

Nuffield Department of Primary Care Health Services. PANORAMIC protocol V1.3. 24

Medicines & Healthcare products Regulatory Agency. Decision. Summary of products characteristics for Lagevrio

Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients

WMA Declaration of Helsinki-Ethical principles for medical research involving human subjects. 64 th WMA General Assembly

Treatments for coronavirus (COVID-19). Page last reviewed 19

Information for healthcare professionals. Recruitment

Medicines & Healthcare products Regulatory Agency. Decision Regulatory approval of Paxlovid 31